Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas
NCT ID: NCT02106312
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 14-037
To study the feasibility of reducing the dose of preoperative radiotherapy in MLS (Myxoid Liposarcomas) from 50 Gy to 36 Gy while maintaining comparable clinicopathological responses.
Brigham and Women's Hospital, Dana-Farber Cancer Institute
Elizabeth Baldini, MD,
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute:
Andrew Crocker, 617-525-8099,
1. Age above or equal to 18 years
2. Biopsy proven MLS (including the reciprocal chromosomal translocation
t(12;16)(q13;p11); A the primary sarcoma in case of non-metastatic disease for
management is with curative intent (regimen to be chosen = 18 x 2 GY) B in case of
oligometastatic patients, the metastasis may also be irradiated to a dose of 36 GY in
order to postpone the time interval to next systemic chemotherapy. These patients are
usually not operated upon and the total dose may also be reached in 12 times 3 Gy,
for convenience purposes (see paragraph 10 for radiobiological considerations).
3. ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) 0-2
4. Patients must be able (physically, mentally and socially) to complete a series of RT,
followed by an observation period of 4-6 weeks and undergo surgery.
5. Written informed consent
1. Prior radiotherapy to the target area.
2. Anticoagulant medication of any kind; especially Ascal®(and derivates), coumarines
(Sintrom® and Marcoumar®), all heparin and heparin-like formulations. (Note: this
exclusion criterion only applies for patients consenting to the translational
research part of the study; patients on anticoagulant medication as described above
may take part in the dose reduction part of the study, but the repeat biopsies may
not be taken.)
3. Pregnancy -